Celoxica Launches Futures Trading Platform

Celoxica has launched a new hardware-accelerated futures trading platform for traders executing low-latency strategies on the CME and InterContinental Exchange (ICE) Liffe and Eurex exchanges, the company said.

With ongoing volatility and escalating market volumes in global futures markets, trading firms are increasingly seeking to capitalize on short-term disparities between pricing on both the US and European futures markets, according to the company in its release.

Celoxica's futures trading platform provides an ultra-low latency market data and trading execution platform with single digit latencies from wire to wire irrespective of market conditions.

Based on FPGA technology the trading platform can accelerate market data into trading algorithms and rapidly execute orders to ensure that fills are met across multiple trading strategies including fixed income, commodities and foreign exchange. Celoxica's FPGA cards are compatible with standard PCIe slots allowing for easy installation as well as increased efficiency achieved through reducing server number and co-location costs.

"For Futures trading, processing speed, determinism and throughput continue to play a crucial role in the success of principle trading firms and hedge funds trading on the global futures markets" stated Jean Marc Bouhelier, Celoxica's Chairman and CEO, in the release. "Celoxica's ability to offer next generation systems to address these key technology and business requirements, whilst ensuring costs are minimized, means our clients and partners can increase focus on their trading strategies for CME, ICE, CFE, Liffe US, Liffe and Eurex, knowing they are using the most efficient trading platform for market data and order execution available on the market today". Ivy is Editor-at-Large for Advanced Trading and Wall Street & Technology. Ivy is responsible for writing in-depth feature articles, daily blogs and news articles with a focus on automated trading in the capital markets. As an industry expert, Ivy has reported on a myriad ... View Full Bio